| $350M | ||
| $217M | ||
| $172M | ||
| $109M | ||
| $107M | ||
| $104M |
Buys | $0 | 0 | 0 |
Sells | $1,949,747 | 4 | 100 |
| Fitzpatrick Alexander A | Chief Legal Officer | 0 | $0 | 1 | $33,550 | $-33,550 |
| Dorsey Brian | Chief Operating Officer | 0 | $0 | 1 | $190,050 | $-190,050 |
| Karas Eric | Chief Commercial Officer | 0 | $0 | 1 | $250,000 | $-250,000 |
| Chakma Justin | Chief Business Officer | 0 | $0 | 1 | $1.48M | $-1.48M |
ARS Pharmaceuticals, Inc. specializes in creating ARS-1, an innovative intranasal epinephrine spray utilizing advanced absorption technology. This product serves as a crucial intervention for individuals and their households who are susceptible to life-threatening allergic reactions caused by food, pharmaceuticals, or insect stings. Among its offerings is Neffy, a low-dose version of its intranasal epinephrine nasal spray. Established in 2015, the firm operates out of San Diego, California.
Over the last 12 months, insiders at ARS Pharmaceuticals, Inc. have bought $0 and sold $1.95M worth of ARS Pharmaceuticals, Inc. stock.
On average, over the past 5 years, insiders at ARS Pharmaceuticals, Inc. have bought $25.62M and sold $28.64M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 505,954 shares for transaction amount of $4.95M was made by RA CAPITAL MANAGEMENT, L.P. () on 2024‑03‑27.
| 2026-06-12 | Sale | Fitzpatrick Alexander A | Chief Legal Officer | 3,355 0.0035% | $10.00 | $33,550 | -42.42% | |
| 2026-06-12 | Sale | Karas Eric | Chief Commercial Officer | 25,000 0.0263% | $10.00 | $250,000 | -42.42% | |
| 2025-11-13 | Sale | Dorsey Brian | Chief Operating Officer | 21,828 0.023% | $8.71 | $190,050 | -2.62% | |
| 2025-11-12 | Sale | Chakma Justin | Chief Business Officer | 166,380 0.1707% | $8.87 | $1.48M | -8.49% | |
| 2025-08-21 | Sale | Lowenthal Richard E | PRESIDENT AND CEO | 50,000 0.0499% | $14.49 | $724,345 | -39.07% | |
| 2025-08-21 | Sale | Scott Kathleen D. | Chief Financial Officer | 12,500 0.0129% | $15.00 | $187,500 | -39.07% | |
| 2025-08-20 | Sale | Tanimoto Sarina | CHIEF MEDICAL OFFICER | 37,656 0.0372% | $14.09 | $530,626 | -37.88% | |
| 2025-08-19 | Sale | Tanimoto Sarina | CHIEF MEDICAL OFFICER | 12,344 0.0129% | $14.03 | $173,130 | -34.23% | |
| 2025-07-01 | Sale | Karas Eric | Chief Commercial Officer | 15,000 0.0161% | $16.99 | $254,861 | -39.59% | |
| 2025-06-27 | Sale | Flynn James E | 10 percent owner | 370,074 0.3822% | $18.46 | $6.83M | -46.29% | |
| 2025-06-18 | Sale | Karas Eric | Chief Commercial Officer | 15,000 0.0154% | $16.00 | $240,000 | -38.47% | |
| 2025-05-20 | Sale | Fitzpatrick Alexander A | Chief Legal Officer | 102,969 0.1031% | $14.10 | $1.45M | -29.80% | |
| 2025-05-20 | Sale | Scott Kathleen D. | Chief Financial Officer | 50,000 0.0501% | $14.10 | $705,165 | -29.80% | |
| 2025-05-20 | Sale | SAUNDERS BRENT L | director | 120,000 0.1215% | $14.25 | $1.71M | -29.80% | |
| 2025-04-07 | Sale | Shawver Laura | director | 50,002 0.0489% | $12.30 | $615,075 | -15.90% | |
| 2025-03-20 | Sale | Karas Eric | Chief Commercial Officer | 10,000 0.0101% | $14.00 | $140,000 | -21.59% | |
| 2025-03-06 | Sale | Shawver Laura | director | 49,600 0.0524% | $11.21 | $556,046 | +6.49% | |
| 2025-03-05 | Sale | Shawver Laura | director | 400 0.0004% | $11.00 | $4,400 | +5.70% | |
| 2025-02-03 | Sale | Shawver Laura | director | 50,000 0.0486% | $12.31 | $615,565 | -4.39% | |
| 2025-01-06 | Sale | Shawver Laura | director | 50,000 0.0511% | $11.10 | $555,065 | +10.60% |
| Fitzpatrick Alexander A | Chief Legal Officer | 90910 0.0914% | $277,275.50 | 2 | 2 | +133.38% |
| RA CAPITAL MANAGEMENT, L.P. | 9958073 10.0134% | $30.37M | 5 | 0 | +46.88% | |
| ORBIMED ADVISORS LLC | director | 0 0% | $0 | 1 | 4 | |
| Thompson Peter A. | director | 0 0% | $0 | 1 | 4 |
$64,733,831 | 40 | 5.69% | $299.32M | |
$140,595,157 | 34 | 17.93% | $301.23M | |
$2,471,510 | 19 | 17.33% | $334.18M | |
$104,171,521 | 16 | 20.21% | $275.53M | |
$1,057,969 | 14 | 68.06% | $271.16M |
| Increased Positions | 94 | +42.15% | 16M | +19.6% |
| Decreased Positions | 92 | -41.26% | 11M | -13.11% |
| New Positions | 36 | New | 10M | New |
| Sold Out Positions | 36 | Sold Out | 4M | Sold Out |
| Total Postitions | 225 | +0.9% | 89M | +6.49% |
| Ra Capital Management, L.P. | $124,793.00 | 10.97% | 10.86M | 0 | 0% | 2025-09-30 |
| Orbimed Advisors Llc | $95,235.00 | 8.37% | 8.29M | 0 | 0% | 2025-09-30 |
| Deerfield Management Company, L.P. | $86,219.00 | 7.58% | 7.5M | -2M | -22.84% | 2025-09-30 |
| Blackrock, Inc. | $55,512.00 | 4.88% | 4.83M | +407,863 | +9.22% | 2025-09-30 |
| Rubric Capital Management Lp | $51,705.00 | 4.55% | 4.5M | +3M | +247.52% | 2025-09-30 |
| Sr One Capital Management, Lp | $46,108.00 | 4.05% | 4.01M | 0 | 0% | 2025-09-30 |
| Vanguard Group Inc | $40,218.00 | 3.54% | 3.5M | +237,630 | +7.28% | 2025-09-30 |
| Aberdeen Group Plc | $35,585.00 | 3.13% | 3.1M | +2M | +106.11% | 2025-09-30 |
| State Street Corp | $33,266.00 | 2.93% | 2.9M | +700,763 | +31.93% | 2025-09-30 |
| Alliancebernstein L.P. | $30,358.00 | 2.67% | 2.64M | -1M | -30.94% | 2025-09-30 |